24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.

NCT02878681 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Visual Impairment Due to Diabetic Macular Edema

Interventions

DRUG: Ranibizumab
DRUG: Aflibercept

Sponsor

Novartis Pharmaceuticals